← Back to Clinical Trials
Recruiting NCT03478761

24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry

Trial Parameters

Condition 24-hydroxylase Deficiency
Sponsor Mayo Clinic
Study Type OBSERVATIONAL
Phase N/A
Enrollment 600
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2017-10-19
Completion 2030-12

Brief Summary

You are being asked to take part in this research registry because you or your family member is suspected to have a 24-hydroxylase deficiency.

Eligibility Criteria

Inclusion Criteria: Patients who have undergone genetic testing for a CYP24A1 mutation with at least 3 of the following: * Urinary Stone Disease * Nephrocalcinosis * Metabolic Bone Disease * Serum Calcium \>/= 9.6 mg/dL * Parathyroid hormone (PTH) \< 30 pg/mL * 1,25-dihydroxyvitamin D \> 40 pg/mL OR a family member of a patient who meets the above criteria Exclusion Criteria: Patients who have tested negative for a CYP24A1 mutation with an alternative diagnosis that might explain hypercalcemia/hypercalciuria/stone disease: * Sarcoidosis * Lymphoma * Tuberculosis * Fungal infections * Excessive exogenous calcium or vitamin D intake

Related Trials